Envestnet Asset Management Inc Zentalis Pharmaceuticals, Inc. Transaction History

Envestnet Asset Management Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	BUY	$17.91 - $52.25 $5,910 - $17,242	330 Added 3.26%	10,462 $294,000
Q1 2022 May 04, 2022	SELL	$41.58 - $80.89 $85,155 - $165,662	-2,048 Reduced 16.81%	10,132 $467,000
Q4 2021 Feb 04, 2022	BUY	$66.92 - $84.79 $815,085 - $1.03 Million	12,180 New	12,180 $1.02 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.